Diabetes and vascular disease: From pathogenesis to treatment. Are vascular effects of hypoglycemic and hypolipidemic drugs independent of their metabolic effects?

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 1, Issue 1, 2007, Pages 61-69

  Škrha, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetes mellitus; Endothelial dysfunction; Lipid lowering drugs; Oral hypoglycemic agents; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN TYPE 4; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE TRANSPORTER 1; GLYCOSAMINOGLYCAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMININ; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROBUCOL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIAGNOSTIC VALUE; DISEASE COURSE; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LASER DOPPLER FLOWMETRY; LIPID PEROXIDATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLETHYSMOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; VASCULAR ENDOTHELIUM;

EID: 34247869811     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2006.11.004     Document Type: Review

References (64)

1. Turner R.C., Millns H., Neil H.A.W., Stratton I.M., Manley S.E., Matthews D.R., et al., For the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 316 (1998) 823-828
2. West I.C. Radicals and oxidative stress in diabetes. Diabet Med 17 (2000) 171-180
3. Giardino I., Edelstein D., and Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 97 (1996) 1422-1428
4. Nishikawa T., Edelstein D., and Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int 58 Suppl. 77 (2000) S26-S30
5. Ahmed M.U., Thorpe S.R., and Baynes J.W. Identification of N-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261 (1986) 4889-4894
6. Stehouwer C.D.A., and Schaper N.C. The pathogenesis of vascular complications of diabetes mellitus: one voice or many?. Eur J Clin Invest 26 (1996) 535-543
7. Thomas M.C., Baynes J.W., Thorpe S.R., and Cooper M.E. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6 (2005) 453-474
8. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
9. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87 (1990) 1620-1624
10. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 (1998) 859-866
11. Gabriele A., and King G.L. Protein kinase C inhibitors in the treatment and prevention of diabetic complications. Curr Opin Endocrinol Diabet 8 (2001) 197-204
12. Škrha J., Hodinář A., Kvasnička J., and Hilgertová J. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabetic Med 13 (1996) 800-805
13. Noberasco G., Odetti P., Boeri D., Maiello M., and Adezati L. Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. Biomed Pharmacother 45 (1991) 193-196
14. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 295 (2006) 1681-1687
15. Haffner S.M., Agil A., Mykkanen L., Stern M.P., and Jialal I. Plasma oxidizability in subjects with normal glucose tolerance and NIDDM. Diabetes Care 18 (1995) 646-653
16. Ceriello A., dello Russo P., Amstad P., and Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Diabetes 45 (1996) 471-477
17. Sharpe P.C., Liu W.H., Yue K.K.M., McMaster D., Catherwood M.A., McGinty A.M., et al. Glucose-induced oxidative stress in vascular contractile cells. Diabetes 47 (1998) 801-809
18. Kawamura N., Ookawara T., Suzuki K., Konishi K., Mino M., and Taniguchi N. Increased glycated Cu,Zn-superoxide dismutase levels in erythrocytes of patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 74 (1992) 1352-1354
19. Hayaishi-Okano R., Yamasaki Y., Kajimoto Y., Sakamoto K., Ohtoshi K., Katakami N., et al. Association of NADPH oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care 26 (2003) 458-463
20. Veves A., Akbari C.M., Primavera J., Donaghue V.M., Zacharoulis D., Chrzan J.S., et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47 (1998) 457-463
21. Curtis T.M., and Scholfield C.N. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diab Metab Res Rev 20 (2004) 28-43
22. Škrha J., Prázný M., Haas T., Kvasnička J., and Kalvodová B. Comparison of laser-Doppler flowmetry with biochemical indicators of endothelial dysfunction related to early microangiopathy in Type 1 diabetic patients. J Diab Compl 15 (2001) 234-240
23. Tesfamariam B., and Cohen R.A. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 263 (1992) H321-H326
24. Schleicher E., and Nerlich A. The role of hyperglycemia in the development of diabetic complications. Horm Metab Rev 28 (1996) 367-373
25. Takei A., Huang Y., and Lopes-Virella F. Intercellular adhesion molecule-1 (ICAM-1) expression induced by oxLDL on human umbilical vein endothelial cells (HUVEC) depends on the stage of LDL oxidation. Diabetes 47 Suppl. 1 (1998) A115
26. Chappey O., Dosquet C., Wautier M.P., and Wautier J.L. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 27 (1997) 97-108
27. Shafrir E., and Raz I. Diabetes: mellitus or lipidus?. Diabetologia 46 (2003) 433-440
28. Forst T., Lubben G., Hohberg C., Kann P., Sachara C., Gottschall V., et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 12 (2005) 543-550
29. Jennings P.E., and Belch J.J.F. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metab Clin Exp 49 Suppl. 1 (2000) 23-26
30. O'Brien R.C., Luo M., Balazs N., and Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diab Complic 14 (2000) 201-206
31. Onozato M.L., Tojo A., Goto A., and Fujita T. Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int 65 (2004) 951-960
32. Kimoto K., Suzuki K., Kizaki T., Hitomi Y., Ishida H., Katsuta H., et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 303 (2003) 112-119
33. Tsubouchi H., Inoguchi T., Inuo M., Kakimoto M., Sonta T., Sonoda N., et al. Sulfonylureas as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic beta-cell line, M1N6-a role of NAD(P)H oxidase in beta-cells. Biochem Biophys Res Commun 326 (2005) 60-65
34. Shimabukuro M., Higa N., and Takasu N. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients-a randomized crossover study. J Diab Compl 20 (2006) 179-183
35. Wierensperger N.F. Metformin intrinsic vasculoprotective properties. Diabetes Technol Ther 2 (2000) 259-272
36. Ouslimani N., Peynet J., Bonnefont-Rousselot D., Therond P., Legrand A., and Beaudeux J.L. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 54 (2005) 829-834
37. Hattori Y., Suzuki K., Hattori S., and Kasai K. Metformin inhibits cytokine-induced nuclear factor kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 47 (2006) 1183-1188
38. Detaille D., Guigas B., Chauvin Ch., Betandier C., Fontaine E., Wierensperger N., et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54 (2005) 2179-2187
39. Bradley J.D., Zhonglin Y., Benoit V., and Ming-Hui Z. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55 (2006) 496-505
40. Gallo A., Ceolotto G., Pinton P., Iori E., Murphy E., Rutter G.A., et al. Metformin prevents glucose-induced protein kinase C-β2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 54 (2005) 1123-1131
41. Majithiya J.B., and Balaraman R. Metformin reduces blood pressure and restores endopthelial function in aorta of streptozotocin-induced diabetic rats. Life Sci 78 (2006) 2615-2624
42. Kraemer de Aguiar L.G., Bahia R.L., Villela N., Laflor C., Sicuro F., Wiernsperger N., et al. Metformin improves endothelial vascular reactivity in first-degree relatives of Type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 29 (2006) 1083-1089
43. Škrha J., Štulc T., Hilgertová J., Weiserová H., Kvasnička J., and Češka R. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol 493 (2004) 183-189
44. Molčanyiová A., Stančáková A., Javorský M., and Tkáč I. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia. Pharmacol Res 54 (2006) 203-207
45. John S., Schneider M.P., Delles C., Jacobi J., and Schmieder R.E. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 149 (2005) Art. No. e10
46. Haas M.J., Horani M.H., Parseghian S.A., and Mooradian A.D. Statins prevent dextrose-induced endothelial barrier dysfunction possibly through inhibition of superoxide formation. Diabetes 55 (2006) 474-479
47. Otto A., Fontaine D., Fontaine J., and Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 46 (2005) 177-184
48. Schaefer C.A., Kuhlmann C.R.W., Weiterer S., Fehsecke A., Abdallah Y., Schaefer C., et al. Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation. Atherosclerosis 185 (2006) 290-296
49. Parmar K.M., Nambudiri V., Dai G.H., Larman H.B., Gimbrone M.A., and Garcia-Cardena G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 280 (2005) 26714-26719
50. Dogra G.K., Watts G.F., Chan D.C., and Stanton K. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabetic Med 22 (2005) 239-242
51. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis-regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
52. Calkin A.C., Cooper M.E., Jandeleit-Dahm K.A., and Allen T.J. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49 (2006) 766-774
53. Bae J.H., Bassenge E., Lee H.J., Park K.R., Park C.G., Park K.Y., et al. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atheroslcerosis 158 (2001) 165-171
54. Han S.H., Quon M.J., and Koh K.K. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 46 (2005) 1086-1092
55. Vinik A.I., Ullal J., Parson H.K., Barlow P.M., and Casellini C.M. Pioglitazone treatment improves nitrosative stress in Type 2 diabetes. Diabetes Care 29 (2006) 869-876
56. Chen J.W., Li D.Y., Zhang X.J., and Mehta J.L. Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone. J Cardiovasc Pharmacol Ther 9 (2004) 35-41
57. Martens F.M.A.C., Rabelink T.J., op't Rood J., de Koning E.J.P., and Visseren F.L.J. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 27 (2006) 1605-1609
58. Campia U., Matuskey L.A., and Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113 (2006) 867-875
59. Martens F.M.A.C., Visseren F.L.J., de Koning E.J.P., and Rabelink T.J. Short-term treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46 (2005) 773-778
60. Sourij H., Zweiker R., and Wascher T.C. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset Type 2 diabetes. Diabetes Care 29 (2006) 1039-1045
61. Dormandy J.A., Charbonnel B., Eckland D.J.A., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
62. Tao L., Liu H.R., Gao E., Teng Z.P., Lopez B.L., Christopher T.A., et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 108 (2003) 2805-2811
63. Choi D., Kim S.K., Choi S.H., Ko Y.G., Ahn C.W., Jang Y., et al. Preventive effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
64. Pistrosch F., Herbrig K., Kindel B., Passauer J., Fischer S., and Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54 (2005) 2206-2211